JAK1 and myeloproliferative disorder: Despite the fact that hyperactive STAT1 signaling is linked to the expansion of abnormal megakaryocytes in myeloproliferative neoplasm (MPN), inhibiting STAT1 tyrosine phosphorylation with the JAK1/2 inhibitor Ruxolitinib has no influence on megakaryocytic differentiation [58].